Regression of endometrial autografts in a rat model of endometriosis treated with etanercept

Mine İslimye, Islimye M, Sevtap Kılıç, Sevtap Kilic, Kilic S, Ebru Zülfikaroğlu, Ebru Zulfikaroglu, Topcu O, Onur Topcu, Zergeroglu S, Sema Zergeroglu, Sema Zergeroğlu, Sertaç Batıoğlu, Sertac Batioglu, Batioglu S
European journal of obstetrics, gynecology, and reproductive biology · 2011 · vol. 159(1) , pp. 184–189 · doi:10.1016/j.ejogrb.2011.06.029 · PMID:21741153 · W2160721484
Other OA: closed CC0 ⤵ 31 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Etanercept treatment in a rat model of endometriosis led to the regression of endometrial autografts.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine the efficacy of anti-tumor necrosis factor therapy (etanercept) for treating endometriosis in the rat endometriosis model. STUDY DESIGN: A randomized, placebo-controlled, blinded study using rat endometriosis model. After the peritoneal implantation of endometrial tissue, twenty-eight Wistar female rats were randomized to two equal intervention groups: the control group and the etanercept-treated group. After measuring implant volume, pretreatment blood and peritoneal fluid samples were obtained. A vehicle treatment of 2 mL saline to the rats in control group and 0. 4 mg/kg etanercept SC once weekly were administered in the etanercept-treated group. After four weeks treatment period, the volumes and histopathological properties of the implants were evaluated. A scoring system was used to evaluate preservation of epithelia. Endometrial explants were evaluated immunohistochemically for tumor necrosis factor receptor type 2 (TNFR2). A scoring system was used to evaluate expression grade of TNFR2. RESULTS: There was not a significant difference in spherical volume between control (131.0 (60.3-501.2)) and treatment groups (72.8 (31.2-149.6)) (p>0.025). There was a significant change in between the volumes of implants before and after treatment in etanercept group (p<0.05). At the end of the treatment significant differences among the groups were found in histopathological and immunohistochemical parameters (p<0.05) also histologic scores and HSCORES were decreased in the treatment group significantly (p<0.05). CONCLUSION: These results indicate that etanercept was found to effectively reduce the development of endometriosis in this experimental rat model.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Disease Models, Animal Disease Models, Animal Endometriosis Endometrium Immunoglobulin G Peritoneal Diseases Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Animals Animals Ascitic Fluid Ascitic Fluid Atrophy Atrophy Atrophy Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (31)

Cited by (30)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:10.644269+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK